SSRIs and SNRIs for depression — patient and clinician information
Customize your policy alerts
Sign up for all sanford health plan policy alerts
Know when sanford health plan releases new policies or updates existing guidance.
Monitor payer policy activity
Patient-facing and clinician information about selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) used to treat depression, including expected onset, common side effects, and safety guidance; applies to Sanford Health Plan members and providers referencing the plan's materials.
No material clinical or coverage changes in this revision.
Coverage Criteria Summary
The policy document does not list any coverage exclusions for SSRIs or SNRIs. There are no procedure or drug codes, prior authorization requirements, step-therapy rules, or explicit denial triggers identified for these medication classes in this guidance.
What Providers Need to Know / Do
No prior authorization listed
The document does not list any procedure or drug codes or state prior authorization requirements for SSRIs or SNRIs.
No step therapy requirements
There are no step therapy or sequencing rules described for initiating SSRIs or SNRIs in this document.
No documentation requirements specified
The policy does not specify required clinical or administrative documentation to support prescribing or coverage of SSRIs/SNRIs.
No authorization or denial triggers stated
The document contains no explicit authorization or denial triggers (no criteria that would require or deny authorization for SSRI/SNRI treatment).
Clinical Background
Depression is described as a medical condition that goes beyond everyday sadness and may cause serious, long‑lasting symptoms that often disrupt a person’s ability to perform routine tasks. Untreated depression is associated with lower quality of life, increased suicide risk, and worse outcomes for coexisting medical conditions. SSRIs and SNRIs are common medication classes used to treat depression; they are generally considered safe and can improve depressive symptoms, but clinicians should counsel patients that most agents take 2–6 weeks before symptom improvement is likely to be noticed. Common early side effects include headache, drowsiness or dizziness, insomnia, nausea, diarrhea or constipation, and possible emergence of suicidal thoughts. Patients should be advised to report severe symptoms immediately—particularly signs of serotonin syndrome (for example, fast heartbeat, shaking or trembling, sweating, vomiting, rapid eye movements, or confusion)—and not to stop or change dosing without first consulting their prescriber because abrupt discontinuation can cause withdrawal‑like symptoms.
Medication Classes Defined
Pharmacotherapy (SSRIs/SNRIs)
Pharmacotherapy (SSRIs/SNRIs) — Medical Necessity Criteria
Covered when ALL of the following are met:
ALL of the following
- ONE of: Patient has a diagnosis of depression or depressive disorder for which pharmacologic treatment with an SSRI or SNRI is clinically indicated based on standard clinical assessment.
- ONE of: Provider documents intent to initiate or continue an SSRI or SNRI as part of the patient’s treatment plan.
- ONE of: Patient/caregiver counseling provided or planned regarding expected time to onset of benefit (typically 2–6 weeks), common side effects (e.g., headache, drowsiness/dizziness, insomnia, nausea, diarrhea or constipation), and warning signs of serious adverse effects including serotonin syndrome (e.g., fast heartbeat, shaking/trembling, sweating, vomiting, rapid eye movements, confusion) and suicidal thoughts; and plan for monitoring and follow-up.
- ONE of: Provider documents plan to instruct patient not to change dose or stop medication without discussing with clinician; if discontinuation is advised, provider documents whether tapering over several days is appropriate to reduce risk of withdrawal-like symptoms (e.g., dizziness, lethargy, headaches, flu-like symptoms).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.